Restelli U, Alberti A, Lazzarin A, et al. Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients. Farmeconomia. Health Economics and Therapeutic Pathways. 2016;17(1):7-12. https://doi.org/10.7175/fe.v17i1.1225